Article
Oncology
Young Hoon Park, Sewon Lee, Yeung-Chul Mun, Dong Jin Park
Summary: This study compared the impact of ELN and mELN criteria on the development of HU resistance or intolerance in high-risk ET patients receiving HU treatment. The mELN criteria were found to more accurately identify HU resistance and intolerance and had an independent prognostic impact on transformation-free survival. The mELN criteria can be used to identify high-risk ET patients who may benefit from second-line therapy.
Article
Oncology
Xiao Huang, Tingting Ma, Yongmei Zhu, Bo Jiao, Shanhe Yu, Kankan Wang, Jian-Qing Mi, Ruibao Ren
Summary: The expression of IRF4 and IRF8 is associated with the MPN phenotype, serving as potential biomarkers for the response to hydroxyurea in ET patients.
FRONTIERS OF MEDICINE
(2022)
Article
Oncology
Swarna Sri Nalluru, Orhan Efe, Yayan Chen, Nitin Trivedi
Summary: This case report describes a rare case of disseminated intravascular coagulation due to the transformation of essential thrombocytosis (ET) to both acute myeloid leukemia (AML) and myelofibrosis while being treated with hydroxyurea for 8 years.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2022)
Article
Cardiac & Cardiovascular Systems
Carlos A. K. Nakashima, Luis A. O. Dallan, Luiz A. F. Lisboa, Fabio B. Jatene, Ludhmila A. Hajjar, Alexandre M. Soeiro, Remo H. M. Furtado, Talia F. Dalcoquio, Luciano M. Baracioli, Felipe G. Lima, Roberto R. C. Giraldez, Bianca A. Silva, Mateus S. S. Costa, Celia M. C. Strunz, Luis R. P. Dallan, Carlos J. D. G. Barbosa, Flavia A. B. Britto, Michael E. Farkouh, Paul A. Gurbel, Jose C. Nicolau
Summary: The platelet reactivity-based strategy is as effective as the standard of care in preventing post-CABG bleeding in ACS patients, while also reducing waiting time and hospital expenses.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Hematology
Kittitat Chiaranairungrot, Komkrich Kaewpreechawat, Chanwit Sajai, Narueporn Pagowong, Nissa Sukarat, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Adisak Tantiworawit, Lalita Norasetthada, Ekarat Rattarittamrong
Summary: This study investigated the prevalence, clinical outcomes, and factors associated with hydroxyurea resistance or intolerance among patients with polycythemia vera and essential thrombocythemia. The study found that patients who had hydroxyurea resistance or intolerance had a significantly increased risk of bleeding events. Low baseline hemoglobin levels, age over 60, and splenomegaly were identified as risk factors for hydroxyurea resistance or intolerance.
Article
Cardiac & Cardiovascular Systems
Tobias Harm, Alexander Bild, Kristina Dittrich, Andreas Goldschmied, Jeremy Nestele, Madhumita Chatterjee, Xiaoqing Fu, Kyra Kolb, Tatsiana Castor, Oliver Borst, Tobias Geisler, Dominik Rath, Michael LaeMmerhofer, Meinrad Gawaz
Summary: The study revealed significant changes in the platelet lipidome in ACS patients, with a particular up-regulation of glycerophospholipids. These lipid alterations may play a role in the pathophysiology of ACS.
CARDIOVASCULAR RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Hernan Cohen Arazi, Daniel Chirino, Juan Pablo Costabel, Camilo A. Pulmari, Alfredo Hirschson Prado, Virginia Barba, Pablo Aguero, Juan Jose Badimon
Summary: The study aimed to assess the predictive value of leuko-platelet index (LPI) in hospitalized patients with acute coronary syndromes (ACS). Results showed that LPI > 24 was associated with a higher risk of combined end point (CEP) and antiplatelet resistance independently of age and GRACE score.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Kiran Sarathy, George A. Wells, Kuljit Singh, Etienne Couture, Aun Yeong Chong, Fraser Rubens, Marie Lordkipanidze, Jean-Francois Tanguay, Derek So
Summary: For patients with acute coronary syndromes requiring coronary artery bypass surgery, a more potent antiplatelet regimen may reduce mortality rates. There are potential clinical benefits in terms of platelet quiescence.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Cardiac & Cardiovascular Systems
Peng-Yu Zhong, Jian-Ping Deng, Jing-Hong Zhao, Lei Peng, Tao Liu, Hao-Yu Wang
Summary: Guided antiplatelet therapy provides better clinical outcomes in patients with ACS compared to conventional therapy, with reduced risks of major adverse cardiovascular events, myocardial infarction, all-cause death, cardiovascular death, and stent thrombosis.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Medicine, General & Internal
Sarah Soh, Yu Rim Shin, Jong-Wook Song, Jun Hyug Choi, Young-Lan Kwak, Jae-Kwang Shim
Summary: This study investigated the association between preoperative platelet reactivity to P2Y(12) antagonists and ischemic and hemorrhagic complications in ACS patients undergoing coronary surgery. The results showed no correlation between platelet inhibitory response to P2Y(12) antagonists and ischemic or hemorrhagic complications.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Dehao Wang, Pei Zhao, Yan Lv, Jing Ming, Ziqing Wang, Erpeng Yang, Yumeng Li, Mingjing Wang, Jicong Niu, Yanyu Zhang, Yan Sun, Yi Chen, Ke Chen, Zhuo Chen, Weiyi Liu, Xiaomei Hu
Summary: Abnormal platelet activation in essential thrombocythemia (ET) leads to thrombosis and affects patient prognosis. Platelet activation-associated proteins, including GPIb alpha, SELP, PF4, MMP1, and FLNA, were found to be significantly elevated in ET patients. Regression analysis showed a positive correlation between SELP levels and the IPSET prognostic score, and a negative correlation between SELP levels and antithrombin (AT-III) levels. Furthermore, inflammatory factors IL-10, IL-12P70, and IL-31 were negatively correlated with both AT-III and SELP levels. These findings suggest that platelet activation-related proteins and serum SELP may serve as prognostic markers in ET patients by promoting leukocyte increase, inflammatory factor expression, and aberrant coagulation.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Hematology
Joachim Kvernberg, Erik Lerkevang Grove, Hans Beier Ommen, Anne-Mette Hvas
Summary: Platelet activation is increased in ET patients, while platelet aggregation is reduced. Further studies are needed to explore markers of thromboembolic risk in ET patients.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2021)
Article
Hematology
Dario Bongiovanni, Nina Schreiner, Rosanna Gosetti, Katharina Mayer, Dominick J. Angiolillo, Dirk Sibbing, Stefan Holdenrieder, Aida Anetsberger, Moritz von Scheidt, Heribert Schunkert, Karl-Ludwig Laugwitz, Stefanie Schuepke, Adnan Kastrati, Isabel Fegers-Wustrow, Isabell Bernlochner
Summary: This study aimed to evaluate immature or reticulated platelets as a predictive biomarker for adverse cardiovascular events in patients with acute coronary syndrome treated with potent P2Y(12) receptor inhibitors. The findings showed that immature platelets were significantly associated with the incidence of the primary endpoint, indicating their potential as a predictive marker for adverse cardiovascular events in these patients.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2023)
Article
Pharmacology & Pharmacy
Alberto Tosetto, Bianca Rocca, Giovanna Petrucci, Silvia Betti, Denise Soldati, Elena Rossi, Andrea Timillero, Viviana Cavalca, Benedetta Porro, Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Alfredo Dragani, Mauro Di Ianni, Paola Ranalli, Francesca Palandri, Nicola Vianelli, Eloise Beggiato, Giuseppe Lanzarone, Marco Ruggeri, Giuseppe Carli, Elena Maria Elli, Stefania Priolo, Maria Luigia Randi, Irene Bertozzi, Giuseppe Gaetano Loscocco, Alessandra Ricco, Giorgina Specchia, Alessandro Maria Vannucchi, Francesco Rodeghiero, Valerio De Stefano, Carlo Patrono
Summary: Essential thrombocythemia (ET) is characterized by enhanced platelet production and thrombotic complications, with the effectiveness of aspirin treatment potentially influenced by platelet count and cytoreductive therapy. Increasing aspirin dosage may reduce variability in treatment response among individuals.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Cardiac & Cardiovascular Systems
Yihong Sun, Lin Feng, Xian Li, Zhe Wang, Runlin Gao, Yangfeng Wu
Summary: In ACS patients on DAPT, advancing age, impaired renal function, thrombolytic treatment, and severe comorbidities were independently associated with a higher risk of in-hospital major bleeding.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Cardiac & Cardiovascular Systems
Peiyue Zhang, Cuiyuan Huang, Haiyin Liu, Mengting Zhang, Li Liu, Yuhong Zhai, Jing Zhang, Jian Yang, Jun Yang
Summary: NFAT is a widely expressed transcriptional activator that is involved in regulating the immune system, heart and brain development, and mediating pathological processes such as cardiac hypertrophy. Oxidative stress, characterized by excessive production of reactive oxygen species, mitochondrial dysfunction, calcium overload, and subsequent lipid peroxidation, inflammation, and apoptosis, is associated with various pathological processes. Calcium overload activates NFAT through the calcium-calcineurin pathway, which is the main regulatory mode of NFAT factors. This review focuses on the effects of NFAT transcription factors on reactive oxygen species production, calcium overload, mitochondrial dysfunction, redox reactions, lipid peroxidation, inflammation, and apoptosis in response to oxidative stress. The aim is to provide a reference for understanding the functions and characteristics of NFAT in different stages of oxidative stress and related potential targets.
JOURNAL OF CARDIOLOGY
(2024)
